(RTTNews) - Genfit (GNFTF, GNFT.PA) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NTZ (nitazoxanide), its investigational small-molecule drug candidate. NTZ has been developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF), marking an important regulatory milestone for the program. G1090N is GENFIT's lead investigationa...
(RTTNews) - Genfit (GNFTF, GNFT.PA) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NTZ (nitazoxanide), its investigational small-molecule drug candidate. NTZ has been developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF), marking an important regulatory milestone for the program. G1090N is GENFIT's lead investigational program within the ACLF segment of its pipeline. The FDA's ODD recognizes the potential of G1090N's active substance to address this severe, rare condition characterized by rapid deterioration, systemic inflammation, and high short-term mortality. The designation follows recent Phase 1 data demonstrating a favorable safety and tolerability profile in healthy volunteers, as well as compelling anti-inflammatory activity across ex vivo models, providing a solid foundation for advancing the program toward initiation of Phase 2 clinical development, targeted for the second half of 2026. ODD also provides development incentives, including FDA regulatory guidance, certain user fee reductions, and eligibility for seven-year U.S. market exclusivity for the designated indication upon FDA approval. GNFTF closed Monday at $7.87 on the OTC Market, down $2.13 or 21.30%. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
China’s government bond yield curve reached its steepest level in about four years, as inflation concerns triggered by the Iran war pile pressure on longer‑term debt. The spread between the 10- and 30-year sovereign bonds’ yields widened by two basis points Monday to 52 basis points, the most since 2022, after a selloff that pushed yields higher across the curve, with longer maturities hit hardest...
China’s government bond yield curve reached its steepest level in about four years, as inflation concerns triggered by the Iran war pile pressure on longer‑term debt. The spread between the 10- and 30-year sovereign bonds’ yields widened by two basis points Monday to 52 basis points, the most since 2022, after a selloff that pushed yields higher across the curve, with longer maturities hit hardest. The move extends last year’s steepening of China’s yield curve, then driven by heavier issuance of long-dated bonds. Now inflation fears are the main force, as rising prices erode the value of future interest payments and drive investors to sell longer maturities. Despite Beijing’s stable debt issuance plans announced last week, rising oil prices from the Middle East conflict threaten to spill over into China, lifting domestic prices and weakening investor appetite for government debt. “Looking ahead, concerns on inflation outlook and ultra-long special sovereign bond supply will likely limit the downside of China bond yield spread,” said Clair Gao , strategist at Nomura International. “How wide it can go would depend on equity market performance, economic data as well as the actual issuance pace of government bonds.” China’s 30-year bond yield held steady at 2.33% in morning trading on Tuesday, and 10-year yield is also little changed at 1.81%. Market sentiment has stabilized for now after the selloff, as President Donald Trump signaled a possible end to the war and floated the removal of oil sanctions. Despite relatively light foreign and domestic positioning in Chinese bonds, the yield curve is expected to steepen further if the war continues, driven by higher inflation expectations and fiscal pressures if oil prices stay high, said Becky Liu , head of China macro strategy at Standard Chartered Bank. The 30‑year bonds will likely remain “vulnerable”, she said, as issuance of long-dated bonds may rise following approval at the National People’s Congress, while reduced r...
Apple (AAPL 2.15%) should almost always be a consideration when looking for a company to invest in. But when exactly is the right time to buy Apple stock? The beloved tech giant recently held a March event to unveil a range of new products. New product announcements are a frequent occurrence for Apple. However, it showcased an exciting new growth catalyst that may justify adding shares now. Here i...
Apple (AAPL 2.15%) should almost always be a consideration when looking for a company to invest in. But when exactly is the right time to buy Apple stock? The beloved tech giant recently held a March event to unveil a range of new products. New product announcements are a frequent occurrence for Apple. However, it showcased an exciting new growth catalyst that may justify adding shares now. Here is what you need to know. Apple is going after new customer segments, an exciting development The March event included several product announcements, and among them was the new MacBook Neo. While Apple offers a wide range of iPhones to appeal to consumers of various budgets, the Mac and MacBook brands have long targeted higher spenders. The new MacBook Neo starts at $599, approximately $500 cheaper than the cheapest MacBook Air. It effectively expands Apple's addressable market in the computer space, and the entry-level segment is a massive piece of the pie. According to data from Computer Intelligence, roughly 27% of retail PCs sold in the United States cost $1,000 or less, so sitting hundreds of dollars below that threshold should give Apple a great opportunity to capture a lot of new customers who may have wanted a MacBook but never could or wanted to spend the money for it. Apple's total hardware sales exceeded $305 billion in 2025. Mac products were only about one-tenth of that. If Apple successfully breaches the low-end computer market, it could represent a sizable boost to its Mac sales. Expand NASDAQ : AAPL Apple Today's Change ( -2.15 %) $ -5.49 Current Price $ 250.27 Key Data Points Market Cap $3.7T Day's Range $ 249.87 - $ 256.32 52wk Range $ 169.21 - $ 288.62 Volume 1.6M Avg Vol 48M Gross Margin 47.33 % Dividend Yield 0.42 % A world-class business at a fair valuation To be fair to prospective stock buyers, Apple is more expensive today after surging nearly 70% over the past few years. But that doesn't mean investors shouldn't buy the stock. Apple currently trades...
dvulikaia/iStock via Getty Images Curaleaf ( CURLF ) is a cannabis operator, a company that produces and sells cannabis products. Currently, they are in a turnaround. While their wider industry may be poised to recover, every company has problems; Curaleaf's need to be sorted out on its own terms. Business Model Curaleaf provides and sells a mixture of medical and adult-use cannabis products in 15...
dvulikaia/iStock via Getty Images Curaleaf ( CURLF ) is a cannabis operator, a company that produces and sells cannabis products. Currently, they are in a turnaround. While their wider industry may be poised to recover, every company has problems; Curaleaf's need to be sorted out on its own terms. Business Model Curaleaf provides and sells a mixture of medical and adult-use cannabis products in 15 states, as well as internationally. This is primarily on a retail basis, but wholesale operations make up about 26% of revenues (as of 2025). Q4 2025 Investor Presentation They operated 159 retail locations at the end of 2025. As cannabis remains illegal at the federal level, interstate logistics are constrained. US State Site Information (2025 Annual Report) Their 15 cultivation sites ensure there is at least one source of product for each state market where they operate. International Site Information (2025 Annual Report) Internationally, this is less of a problem. A handful of cultivation sites serve the overall needs. Instead of operating their own dispensaries, this is where they primarily operate as wholesalers to local distributors. Branded Products (Q4 2025 Investor Presentation) Their offering covers a wide variety across many brands: smokables, edibles, oils, beverages, and others. Financial History Curaleaf's financial history is a good microcosm of what happened to cannabis as an industry. It grew fast in the 2010s, was given a boost by COVID in 2020, and then suddenly the growth petered out and stopped. Author's display of SEC data We see this with Curaleaf's history, starting at a few million in revenue in 2016 and breaching $1B in 2021. While it edged up for a couple more years, the trend reversed after 2023. Explanations are many, but one I believe is that, as people went back to work and were no longer under lockdown, cannabis use to pass the time declined. In essence, it was the first sign that cannabis may no longer be a growth industry but a cyclical on...
President Donald Trump has signaled a potential end to the conflict by proposing to waive sanctions and deploy the US Navy to protect tankers. Bloomberg’s Laura Davison and Nicholas Lua debate whether these moves can actually stabilize global oil markets. (Source: Bloomberg)
President Donald Trump has signaled a potential end to the conflict by proposing to waive sanctions and deploy the US Navy to protect tankers. Bloomberg’s Laura Davison and Nicholas Lua debate whether these moves can actually stabilize global oil markets. (Source: Bloomberg)